Phio Pharmaceuticals Corp. · NASDAQ:PHIO
Phio Pharmaceuticals — Investor Presentation (January 2023)
18 slides from Phio Pharmaceuticals's investor presentation, Jan 6, 2023
Slide 1: Phio Pharmaceuticals: Proprietary Innovations in Immuno-oncology Therapeutic Applications
1 www.phiopharma.com I Ticker: PHIO (NASDAQ) Phio Pharmaceuticals Proprietary Innovations in Immuno - oncology (I/O) Therapeutic Applications
Slide 2: Forward Looking Statements
2 This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests” and similar expressions are intend ed to identif
Slide 3: Phio Pharmaceuticals: A History of Innovation
• Founded by Nobel Laureate Craig Mello who discovered RNAi • RNAi has broad therapeutic applications across multiple cell types • Phio focuses on Immuno - oncology therapy in dermatological cancers Phio Pharmaceuticals: A History of Innovation
Slide 4: INTASYL Technology and Compounds
4 www.phiopharma.com I Ticker: PHIO (NASDAQ) INTASYL Technology and Compounds
Slide 5: INTASYL: Continuing the Innovation Today
INTASYL Ρ • Patented, self - delivering RNAi technology • Effective against multiple gene targets • Silences genes that tumors utilize to evade the immune system • Makes immune cells more effective in killing cancer cells Continuing the Innovation Today
Slide 6: What Makes INTASYL Unique
• Chemically modified siRNAs precisely target any cell type • Simplified structure enables naked compound delivery — No specialized formulations or delivery systems • Adaptable for use in both Intratumoral and Adoptive Cell Therapy • Efficient in multiple gene targeting compared to gene editing What
Slide 7: INTASYL Pipeline Portfolio
7 Program Target(s) & Indication Discovery Preclinical Proof of Concept Product Development IND Enabling Studies IND Filing or equivalent Pilot Clinical Studies Pivotal Clinical Studies PH - 762 (US) PD - 1 cSCC, Metastatic Melanoma, HNSCC PH - 762 (EU) PD - 1 Metastatic Melanoma PH - 762 Enhanced T
Slide 8: INTASYL Market Potential
8 www.phiopharma.com I Ticker: PHIO (NASDAQ) INTASYL Market Potential
Slide 9: Market Potential for Immuno-oncology
• Underserved need — 3.5 million incidences of solid tumors each year in US • $123 b estimated market revenue in 2023 in direct solid tumor cancer treatments • Determinate success factors for therapies — Efficacy, safety, tolerability, convenience, pharma - economics Market potential for Immuno - on
Slide 10: Potential for cSCC and Melanoma Treatment
10 Potential for Cutaneous Squamous Cell Carcinoma (cSCC) and Melanoma Treatment cSCC incidence: 51% (1.8 m patients) Melanoma incidence: 3% (100,000 patients) All solid tumors, excluding basal cell carcinoma
Slide 11: Underserved Medical Needs in cSCC
• Metastatic patients: ~3.5% • ~ 50% non - responsive to treatment with monoclonal antibodies — some subject to off target auto - immune side effects • Neoadjuvant procedure with INTASYL may offer ‘tissue sparing’ via tumor shrinkage Underserved Medical Needs in cSCC
Slide 12: Competitive Landscape
12 www.phiopharma.com I Ticker: PHIO (NASDAQ) Competitive Landscape
Slide 13: Unique Position: Compete, Stand Alone, Collaborate
13 Unique Position Compete Stand Alone Collaborate
Slide 14: Collaboration Strategy
• Partnerships: Complimentary Co - development — AgonOx relationship : TILs & PH762 — Antibody companies — Other cell therapy: NK cells • Out licensing — INTASYL compounds Collaboration Strategy
Slide 15: Phio Pharmaceuticals Leadership and Finance
15 www.phiopharma.com I Ticker: PHIO (NASDAQ) Phio Pharmaceuticals Leadership and Finance
Slide 16: Leadership
• Robert Bitterman /Executive Chairman • Linda Mahoney/VP Project Development • James Cardia, PhD, VP of Scientific Operations • Caitlin Kontulis , VP Finance Leadership
Slide 17: Financial Summary
17 Combined Peak Year Revenues ~$ .75B to $1.1B 762 IT/ACT Melanoma, cSCC and HNSCC Projected NPV ~$200M to $470MM Cash (at 12/31/2022) ~$11.0MM Burn rate $3.0M / quarter Cash runway Q4 2023 Common shares outstanding (as of 12/31 /2022 ) 13.7M Market Cap (as of 12/31/2022 ) $5.1M Shareholder approva
Slide 18: Thank you.
18 www.phiopharma.com I Ticker: PHIO (NASDAQ) Thank you.
Phio Pharmaceuticals — Investor Presentation (January 2023) on 6ix